THU545 Growth Hormone Receptor Antagonist As A Novel Combination Therapy Against Triple Negative Breast Cancer

Disclosure: P. Mora-Criollo: None. R. Basu: None. J.J. Kopchick: None. Triple Negative breast (TNBC) cancer is classified based on the absence of ER-, PR-, and HER2- receptors and is associated with high metastatic potential. TNBC accounts for approximately 15-20% of new breast cancer diagnoses and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mora-Criollo, Patricia, Basu, Reetobrata, Kopchick, John Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Tumor Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555349/
http://dx.doi.org/10.1210/jendso/bvad114.2171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555349/
http://dx.doi.org/10.1210/jendso/bvad114.2171

Ejemplares similares